$Novavax(NVAX)$ The conference

$Novavax(NVAX)$ The conference call confirmed that additional deals for Matrix M and other protein vaccines “as well as egg based vaccines”. . This is massive news as it opens up huge potential revenue streams with zero dev or extra manufacturing cost. For example, the Equine vaccine market is approximately $1.8 billion. The conference call confirmed that initial testing shows that Matrix M boosts efficacy and longevity and since antigen can be reduced it makes the vaccine cheaper to make and since there’s less antigen there’s fewer/reduced side effects. There is very real potential for billions of dollars annually that Matrix M can capture. Cash Cow = Matrix M + Nuvaxovid + NanoFlu + RSV + H5N1 + R21/Matrix M + H5N1 Inhalable + Sanofi opportunities. The future is company similar to BNTX but with more vaccines and more sales and more profits and a massive Market Cap.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"detailType":1,"isChannel":false,"data":{"magic":2,"id":336563281702952,"tweetId":"336563281702952","gmtCreate":1723204524950,"gmtModify":1723204529596,"author":{"id":9000000000000355,"idStr":"9000000000000355","authorId":9000000000000355,"authorIdStr":"9000000000000355","name":"cozyzi","avatar":"https://static.tigerbbs.com/60528b508747d2305a5e8066c4645143","vip":8,"userType":8,"introduction":"","boolIsFan":false,"boolIsHead":false,"crmLevel":1,"crmLevelSwitch":0,"individualDisplayBadges":[],"fanSize":129,"starInvestorFlag":false},"themes":[],"images":[],"coverImages":[],"html":"<html><head></head><body><p> <a data-mention-id=\"NVAX\" class=\"teditor-mention\" data-mention-name=\"Novavax\" href=\"https://ttm.financial/S/NVAX\">$Novavax(NVAX)$</a> The conference call confirmed that additional deals for Matrix M and other protein vaccines “as well as egg based vaccines”. . This is massive news as it opens up huge potential revenue streams with zero dev or extra manufacturing cost. For example, the Equine vaccine market is approximately $1.8 billion. The conference call confirmed that initial testing shows that Matrix M boosts efficacy and longevity and since antigen can be reduced it makes the vaccine cheaper to make and since there’s less antigen there’s fewer/reduced side effects. There is very real potential for billions of dollars annually that Matrix M can capture. Cash Cow = Matrix M + Nuvaxovid + NanoFlu + RSV + H5N1 + R21/Matrix M + H5N1 Inhalable + Sanofi opportunities. The future is company similar to BNTX but with more vaccines and more sales and more profits and a massive Market Cap.</p></body></html>","htmlText":"<html><head></head><body><p> <a data-mention-id=\"NVAX\" class=\"teditor-mention\" data-mention-name=\"Novavax\" href=\"https://ttm.financial/S/NVAX\">$Novavax(NVAX)$</a> The conference call confirmed that additional deals for Matrix M and other protein vaccines “as well as egg based vaccines”. . This is massive news as it opens up huge potential revenue streams with zero dev or extra manufacturing cost. For example, the Equine vaccine market is approximately $1.8 billion. The conference call confirmed that initial testing shows that Matrix M boosts efficacy and longevity and since antigen can be reduced it makes the vaccine cheaper to make and since there’s less antigen there’s fewer/reduced side effects. There is very real potential for billions of dollars annually that Matrix M can capture. Cash Cow = Matrix M + Nuvaxovid + NanoFlu + RSV + H5N1 + R21/Matrix M + H5N1 Inhalable + Sanofi opportunities. The future is company similar to BNTX but with more vaccines and more sales and more profits and a massive Market Cap.</p></body></html>","text":"$Novavax(NVAX)$ The conference call confirmed that additional deals for Matrix M and other protein vaccines “as well as egg based vaccines”. . This is massive news as it opens up huge potential revenue streams with zero dev or extra manufacturing cost. For example, the Equine vaccine market is approximately $1.8 billion. The conference call confirmed that initial testing shows that Matrix M boosts efficacy and longevity and since antigen can be reduced it makes the vaccine cheaper to make and since there’s less antigen there’s fewer/reduced side effects. There is very real potential for billions of dollars annually that Matrix M can capture. Cash Cow = Matrix M + Nuvaxovid + NanoFlu + RSV + H5N1 + R21/Matrix M + H5N1 Inhalable + Sanofi opportunities. The future is company similar to BNTX but with more vaccines and more sales and more profits and a massive Market Cap.","highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"favoriteSize":0,"link":"https://ttm.financial/post/336563281702952","repostId":0,"isVote":1,"tweetType":1,"viewCount":397,"commentLimit":10,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"symbols":["NVAX"],"verified":2,"subType":0,"readableState":1,"langContent":"EN","currentLanguage":"EN","warmUpFlag":false,"orderFlag":false,"shareable":true,"causeOfNotShareable":"","featuresForAnalytics":[],"commentAndTweetFlag":false,"andRepostAutoSelectedFlag":false,"upFlag":false,"length":733,"xxTargetLangEnum":"ORIG"},"commentList":[],"isCommentEnd":true,"isTiger":false,"isWeiXinMini":false,"url":"/m/post/336563281702952"}